Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Quarterly Statistics, Q3 2016

Executive Summary

A review of biopharma start-up dealmaking and financing from July through September 2016, based on data from Strategic Transactions.

Advertisement

Related Content

IPO Update: Novan, AC Immune End Summer Slowdown As Market Improves
Boehringer Gets Option To Buy ViraTherapeutics And Cancer Virus Therapy
Tech Transfer Roundup: Voyager Brings Home Pair Of CNS Collaborations
VC Roundup: Relay Raises $57m To Seek Drug Targets Among Proteins In Motion
VC Roundup: Moderna Seeks Another Record-Breaking Raise; Arcus Emerges From Stealth Mode
Denali Builds Neurodegeneration Pipeline Through Discovery, Collaborations And Lots Of Cash
Start-Up Quarterly Statistics, Q2 2016
VC Roundup: Cleave Raises $37m To Maintain Phase I Momentum, Plus $233.5m In Recent Financings
Jounce Gets $261m To Start, Milestone Fees Up To $2.3bn In Celgene Deal
Record CStone Funding Heralds New Era For China Startups

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097458

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel